PIRS
PIRS Real Time Price USDRecent trades of PIRS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in PIRS holdings by institutional investors
Quarterly net insider trading by PIRS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
PIRS Estimated quarterly lobbying spending
PIRS Revenue by Segment or Geography
New PIRS patent grants
-
Patent Title: Proteins specific for cd137 Jan. 14, 2025
-
Patent Title: Anti-cancer fusion polypeptide capable of binding both cd137 and glypican-3 (gpc3) Mar. 05, 2024
-
Patent Title: Lipocalin muteins with binding affinity for lag-3 Oct. 03, 2023
-
Patent Title: Engineered t cells and uses therefor Jul. 12, 2022
-
Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Jul. 12, 2022
-
Patent Title: Specific-binding polypeptides and uses thereof May. 31, 2022
-
Patent Title: Proteins specific for cd137 Mar. 01, 2022
-
Patent Title: Lipocalin muteins with binding affinity for lag-3 Nov. 09, 2021
-
Patent Title: Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hngal) which bind angiopoietin-2 (ang-2) Jun. 15, 2021
-
Patent Title: Proteins specific for calcitonin gene-related peptide Jun. 15, 2021
-
Patent Title: Fusion molecules Mar. 16, 2021
-
Patent Title: Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (lag3) and method of use thereof to stimulate an immune response Feb. 23, 2021
-
Patent Title: Multi-specific polypeptide useful for localized tumor immunomodulation Feb. 23, 2021
-
Patent Title: Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides Feb. 09, 2021
-
Patent Title: Anti-cancer fusion polypeptide Dec. 15, 2020
-
Patent Title: Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) Sep. 29, 2020
-
Patent Title: Specific-binding polypeptides and uses thereof Sep. 15, 2020
-
Patent Title: Interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereof Jan. 07, 2020
-
Patent Title: Human neutrophil gelatinase-associated lipocalin (hngal) muteins capable of binding angiopoietin-2 (ang-2) and methods of use thereof Jan. 07, 2020
-
Patent Title: Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (lag-3) and methods of use thereof Dec. 10, 2019
-
Patent Title: Proteins specific for calcitonin gene-related peptide Sep. 03, 2019
-
Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Sep. 03, 2019
-
Patent Title: Tear lipocalin muteins binding il-4 r alpha Mar. 19, 2019
-
Patent Title: Methods and compositions for treating disorders Sep. 04, 2018
-
Patent Title: Muteins of tear lipocalin and methods for obtaining the same Aug. 14, 2018
-
Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Jul. 10, 2018
-
Patent Title: Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation Apr. 24, 2018
-
Patent Title: Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same Sep. 05, 2017
-
Patent Title: Tear lipocalin muteins binding il-4 r alpha Jun. 27, 2017
-
Patent Title: Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation Apr. 04, 2017
-
Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Feb. 21, 2017
-
Patent Title: Muteins of human lipocalin 2 (lcnc,hngal) with affinity for a given target Jan. 24, 2017
-
Patent Title: Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 Dec. 20, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to PIRS from public contracts
Recent insights relating to PIRS
Recent picks made for PIRS stock on CNBC
ETFs with the largest estimated holdings in PIRS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $PIRS stock a Buy, Sell, or Hold?
- What is the price target for $PIRS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $PIRS stock?
- Who owns the most shares of $PIRS stock?
- What funds own $PIRS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PIRS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
No description available